RecruitingPhase 1NCT06730659
A Clinical Study of CHT101 in CD70-Positive Advanced Solid Tumors
A Single-Arm, Open-Label, Phase I Study of CHT101 for CD70-Positive Relapsed/Refractory Solid Tumors
Sponsor
Tianjin Medical University Cancer Institute and Hospital
Enrollment
36 participants
Start Date
Apr 19, 2024
Study Type
INTERVENTIONAL
Conditions
Summary
Evaluate the safety and efficacy of CD70-targeting UCAR-T cells in the treatment of CD70-positive advanced solid tumors.
Eligibility
Min Age: 18 YearsMax Age: 70 Years
Inclusion Criteria8
- Ability to understand and sign a written informed consent documen；
- At the date of signing ICF, 18 ~70 years old, male or female；
- Histopathological confirmed advanced or metastatic solid tumors patients who have failed to standard treatment or intolerance with standard treatment；
- Positive CD70 expression;
- At least one measurable lesion at baseline per RECIST version 1.1；
- The expected survival time is more than 12 weeks;
- ECOG 0-1 points;
- Adequate organ functions;
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
BIOLOGICALCHT101
CHT101: CD 70 UCAR T
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06730659